Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

BMS Starts Nivolumab China Study Amid Rising Local Competition

This article was originally published in PharmAsia News

Executive Summary

Major US immuno-oncology player Bristol-Myers Squibb is racing to gain a nod for Opdivo in China, where a dozen or so companies are already developing PD-1 and PD-1 inhibitors, one of which has been out-licensed to Merck & Co.



Related Companies